

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 812 829 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

17.12.1997 Bulletin 1997/51

(51) Int. Cl.<sup>8</sup>: **C07D 233/54**, A61K 31/415(21) Application number: **96401297.5**(22) Date of filing: **14.06.1996**


(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB IT LI NL SE**• **Sarshar, Sepehr****Cardiff, California 92007 (US)**(71) Applicant: **ONTOGEN CORPORATION****Carlsbad, CA 92009 (US)**(74) Representative: **Sauvage, Renée****Cabinet Sauvage****100 bis, avenue de Saint-Mandé****75012 Paris (FR)**

(72) Inventors:

• **Mjalli, Adnan Mukhabur****Vista, California 92083 (US)**(54) **Substituted imidazoles as modulators of multi-drug resistance**

(57) This invention relates to compounds of Formula 1 which are pharmacologically useful for the treatment of cancer through sensitization of multi-drug resistant cancer cells to chemotherapeutic agents.



Formula 1

wherein  $R_1$ ,  $R_2$ ,  $R_3$ , and  $R_4$  are, for example, alkyl, aryl, etc., which are defined more specifically hereinafter.

EP 0 812 829 A1































































